BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35960100)

  • 1. GIV is a promising novel poor prognostic factor in liver hepatocellular carcinoma.
    Zou Z; Sun Y; Wang L; Ma S; Sun C; Zhou Y; Yang G
    Medicine (Baltimore); 2022 Aug; 101(32):e29645. PubMed ID: 35960100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Significance of
    Li Z; Cui Y; Duan Q; Zhang J; Shao D; Cao X; Gao Y; Wang S; Li J; Jones OD; Lei X; Wang L; Zhou X; Xu M; Ma J; Liu Y; Xu X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
    Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
    Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
    PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.
    Liang C; Long K; Zheng W; Zhong R; Li Z; Zhu S; Gu S; Zhu C; Yang Y
    Medicine (Baltimore); 2024 May; 103(18):e38028. PubMed ID: 38701314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel prognostic biomarker:
    Lai T; Peng T; Li J; Jiang Y; Liu K; Yu W; Yao N; Hu Y; Cao M; Liang J
    Transl Cancer Res; 2023 May; 12(5):1145-1164. PubMed ID: 37304536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
    He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
    Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.
    Yu S; Yang Y; Yang H; Peng L; Wu Z; Sun L; Wu Z; Yu X; Yin X
    Sci Rep; 2023 May; 13(1):7560. PubMed ID: 37161008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index.
    Bai KH; He SY; Shu LL; Wang WD; Lin SY; Zhang QY; Li L; Cheng L; Dai YJ
    Cancer Med; 2020 Jun; 9(12):4290-4298. PubMed ID: 32311840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients.
    Yang Y; Zhao W; Du J; Wang Y
    Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
    Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
    Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.
    Li S; Xue P; Diao X; Fan QY; Ye K; Tang XM; Liu J; Huang ZY; Tang QH; Jia CY; Xin R; Lv ZW; Liu JB; Ma YS; Fu D
    J Adv Res; 2023 Dec; 54():133-146. PubMed ID: 36716957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
    Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
    Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis.
    Han X; Long W; Liu Y; Xu J
    Front Surg; 2022; 9():985034. PubMed ID: 36338652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.
    Wang Y; Liu T; Zhang K; Huang RH; Jiang L
    Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma.
    Zhang C; Xu H; Sui X; Wu T; Chen B; Wang S; Wang X
    J Immunol Res; 2022; 2022():7073472. PubMed ID: 35983074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma.
    Shi L; Shang X; Nie K; Lin Z; Zheng M; Wang M; Yuan H; Zhu Z
    J Clin Pathol; 2021 Aug; 74(8):504-512. PubMed ID: 33004423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma.
    Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X
    Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186
    [No Abstract]   [Full Text] [Related]  

  • 20.
    Tan Z; Chen M; Peng F; Yang P; Peng Z; Zhang Z; Li X; Zhu X; Zhang L; Zhao Y; Liu Y
    Transl Cancer Res; 2022 Aug; 11(8):2713-2732. PubMed ID: 36093522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.